VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Phase 1/2 Terminated 23 enrolled Washington University School of Medicine Tyrogenex · collab

Non-randomizedSequentialOpen-labelTreatment

This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.

Evaluation	Drug	Modality	Dose	Route
Subject	CM082	Unknown	100 mg	Oral
Subject	CM082	Unknown	150 mg	Oral
Subject	CM082	Unknown	200 mg	Oral
Subject	CM082	Unknown	300 mg	Oral
Subject	CM082	Unknown	400 mg	Oral
Subject	Everolimus	Small molecule	10 mg	Oral